Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus HALDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus HALDRONE.
CORTENEMA vs HALDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Glucocorticoid receptor agonist; suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene transcription.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Oral: Initial dose 50-100 mg twice daily; maintenance 25-50 mg twice daily. Maximum 200 mg/day.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life: 2.6-3.8 hours. Clinical context: Short half-life requires multiple daily dosing; no significant accumulation with regular dosing.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal: 20-30% as unchanged drug; biliary/fecal: 70-80% as metabolites and unchanged drug.
Category C
Category C
Corticosteroid
Corticosteroid